EnteroMedics Inc.
Weight loss: EnteroMedics’ losses widen as company seeks FDA approval
Weight loss: FDA accepts EnteroMedics’ submission of VBLOC neurostim implant
Weight loss: EnteroMedics submits Maestro nerve-blocking implant for FDA review
Neurostimulation devices maker EnteroMedics (NSDQ:ETRM) officially submitted its pre-market approval application to the FDA for review of the Maestro VBLOC neuro-blocking system in treatment of obesity, metabolic diseases and other gastrointestinal disorders.
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics (NSDQ:ETRM) said it expects to submit a pre-market approval application to the FDA this quarter for its Maestro rechargeable vagal blocking therapy to treat obesity.
EnteroMedics’ losses soar and shares fall short of Wall Street expectations
Wall Street sent St. Paul, Minn.-based obesity and GI device maker EnteroMedics’ (NSDQ:ETRM) shares down 8% today after the company missed analysts’ consensus estimate.
Weight loss: EnteroMedics closes $13M round | Wall Street Beat
EnteroMedics (NSDQ:ETRM) said it closed a public offering it expects to add about $12 million to its coffers after it pays off expenses.
The St. Paul, Minn.-based medical device company is developing technology to treat obesity using neurostimulation of the vagus nerve to suppress the appetite.
Weight loss: EnteroMedics names new operating chief ahead of FDA bid
Minnesota weight-loss devices maker EnteroMedics (NSDQ:ETRM) announced today that CFO and senior vice president Greg Lea had also been appointed chief operating officer.
Stryker hits a 52-week high | Wall Street Beat
Shares of Stryker (NYSE:SYK) hit a 52-week high yesterday, peaking at $64.46 apeice before closing at $63.88, down 0.2% on the day.
STK shares are up about 3% since the medical device company reported 4th-quarter and 2012 results Jan. 24. Stryker said yesteday that it plans to issue a 26.5¢ dividend to shareholders.
Weight loss: EnteroMedics shares tank after device “fails” study
Wall Street fled in droves after weight-loss devices maker EnteroMedics (NSDQ:ETRM) announced that its Maestro vagal blocking system failed to meet endpoints in a pivotal study, but the mass exodus isn’t discouraging the company from moving forward with a bid for FDA approval.
EnteroMedics cuts losses in Q3, aims for 2014 commercialization
EnteroMedics (NSDQ:ETRM) narrowed its losses during its 3rd quarter, cutting its research & development expenses nearly in half.